Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

SAN DIEGO, May 6, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The faster insulin absorption and shorter duration of action observed in our first ultrafast insulin pump study is exciting," stated Gregory I. Frost, Ph.D., Halozyme's president and CEO. "Patients with diabetes that use insulin pumps could see unique benefits from Halozyme's Ultrafast Insulin."

First Quarter 2011 and Recent Business Highlights

  • Halozyme presented preliminary results from its first Ultrafast Insulin study in type 1 diabetes patients who receive their treatment with an insulin pump demonstrating that Aspart-PH20 generates a faster-in and faster-out profile with accelerated insulin absorption and a shorter duration of action compared to aspart alone. Aspart-PH20 is a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) enzyme with the active ingredient in NovoLog® that was administered as a continuous subcutaneous insulin infusion over 72 hours with an insulin pump. Halozyme presented these results at the American Association of Clinical Endocrinologists meeting in San Diego on April 14, 2011.  
  • American Diabetes Association (ADA) 71s
    '/>"/>

    • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    4. Halozyme Receives $5.5 Million Payment From Baxter
    5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
    (Date:6/18/2013)... Tabletop SEMs are inexpensive and easy to ... performance and capability such as small sample sizes, lower ... provide better imaging performance and more analytical capability but ... higher cost of maintenance. The Pemtron PS-230 and ... types of SEM product, offering competitive prices compared with ...
    (Date:6/18/2013)... (PRWEB) June 18, 2013 In support ... sustainability, the Consulate General of Switzerland in New York ... Switzerland’s MS Tûranor PlanetSolar , to Manhattan. ... its DeepWater Expedition 2013 tour with scientists on board ... Capitain Gérard d’Aboville, runs exclusively on energy from the ...
    (Date:6/18/2013)... Philadelphia, PA (PRWEB) June 18, 2013 ... fiber-optic Ball Lenses engineered of synthetic Sapphire and Glass ... stock sizes from Swiss Jewel Company , of ... performance by expanding and collimating the light beams without ... extreme optical clarity and natural durability (9 mohs) make ...
    Breaking Biology Technology:‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2
    ... Incorporated (Nasdaq: SPEX ), an innovator in ... and regulatory consulting services to food, supplement, biotechnology and ... the 2009 BIO International Conference in Atlanta, Georgia on ... Control Drug" booth will showcase their ongoing global phase ...
    ... Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action ... May 14 VIA Pharmaceuticals, Inc. (Nasdaq: ... of compounds for the treatment of cardiovascular and metabolic ... a Phase 2 clinical trial of its lead drug, ...
    ... manufacturing facility opens with substantially increased capacity, ... Biosystems Inc. (TSX:MBX) announced today robust double digit growth ... for the second quarter ended March 31, 2009. , ... of Microbix said "Our 43% growth in the first ...
    Cached Biology Technology:Spherix to Exhibit at the BIO 2009 International Convention 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4
    (Date:6/18/2013)... of breast and ovarian cancers are familial in origin, ... to inherited mutations from the parents in genes such ... PARP inhibitors, which are currently in clinical trials, have ... for personalised cancer treatment, an alternative to standard chemotherapy. ... these patients generate resistance to the drug and, therefore, ...
    (Date:6/18/2013)... of internationally recognized feline experts including veterinarians and feline ... of Lincoln, U.K. and Dr Ilona Rodan, Director of ... International Society of Feline Medicine (ISFM) and the American ... veterinarians, owners and those working with cats on how ... The new guidelines appear in the Journal of ...
    (Date:6/17/2013)... high levels of air pollution while pregnant were up to ... women who lived in areas with low pollution, according to ... It is the first large national study to examine links ... findings raise concerns since, depending on the pollutant, 20% to ... where risk of autism was elevated," said lead author Andrea ...
    Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
    ... team of Chinese and Swedish researchers rediscovered the breeding area ... the Qinling mountains, Shaanxi province, north central China. Seven ... Changqing National Nature Reserves which almost equals the total ... in the late 19th century. Nearly all of the birds ...
    ...  Today IBM (NYSE: IBM ) formally unveiled the sixth annual ... innovations that have the potential to change the way people work, ... http://photos.prnewswire.com/prnh/20111219/NY24596 ) (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO ) ... , You will never need a ...
    ... Philadelphia, PA -- The Academy of Nutrition and Dietetics ... for Medicare and Medicaid Services (CMS) to expand coverage ... hypertension, obesity, and cancer, as part of the CMS ... conditions can be controlled or treated with medical nutrition ...
    Cached Biology News:Sensational bird finding in China 2Sensational bird finding in China 3IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 2IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 3IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 4IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 5IBM Reveals Five Innovations That Will Change Our Lives Within Five Years 6The Academy of Nutrition and Dietetics advocates for expanded nutritional coverage under Medicare 2The Academy of Nutrition and Dietetics advocates for expanded nutritional coverage under Medicare 3
    ... offers the same benefits as the VSO valve ... is critical or flow is required below 600 ... of gas in proportion to the input current., ... width modulation; closed loop feedback delivers optimal system ...
    ... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
    ... Captiva 96-well Filter Plates are offered in ... 0.45 um depth filter plates are ideal ... analysis. Filtration is simple, versatile, and necessary ... The Captiva 10 um glass fiber and ...
    ... cDNA Labeling System - dUTP with ... For the generation and purification of ... packaged together for complete cDNA labeling ... be used for performing labeling reactions ...
    Biology Products: